Navigation Links
BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013

BOTHELL, Wash., Aug. 12, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced record revenue for the second quarter of 2013 of $2.3 million, including core HypoThermosol® and CryoStor® product revenue of $0.9 million. The increase in total revenue represented 8% sequential growth over the first quarter of 2013 and 112% growth over the second quarter of 2012.


Summary of Achievements for the Second Quarter of 2013

  • Total revenue of $2.3 million marked twelve consecutive quarters of record revenue with an increase of 112% over the second quarter of 2012 and 8% over the first quarter of 2013.
  • Core product revenue was $0.9 million, setting a new record for the Company, driven by demand from the regenerative medicine market segment.
  • We announced a strategic relationship with HemaCare Corporation, wherein HemaCare will market BioLife's HypoThermosol and CryoStor biopreservation media products and HemaCare's blood derived cells to the research and clinical communities.
  • We were named by Seattle Business Magazine as one of the best places to work in Washington State. For more information please visit BioLife Solutions - 100 Best Companies.
  • Mike Rice, BioLife Solutions President and CEO, remarked on the Company's second quarter revenue by stating, "We are pleased with the growth in total revenue and our core product revenue during the second quarter of 2013. Several orders were from new customers as we continue to see evidence of adoption of our proprietary HypoThermosol and CryoStor biopreservation media products."

    Mr. Rice continued, "We saw growth in a number of our strategic markets during the second quarter, including regenerative medicine, where our HypoThermosol® cell/tissue storage medium and CryoStor® cryopreservation freeze media products are being used in more than fifty clinical trial-stage cell and tissue-based therapies. We also gained several new customers in the hair restoration field, where HypoThermosol is increasingly being used for ex vivo storage of hair grafts during the transplantation procedure. The 1,000+ member International Society of Hair Transplantation Surgeons (ISHRS) estimates that nearly 300,000 procedures were performed in 2010, representing a niche, but attractive, $25 million addressable market. Finally, we fulfilled all orders for a strategic contract manufacturing services customer, marking our highest quarter to date for contract manufacturing services revenue."

    Second Quarter 2013 and Year to Date Financial ResultsTotal revenue for the second quarter and first half of 2013 was $2.3 million and $4.5 million, respectively, compared to $1.1 million and $1.9 million in the same periods of 2012. The increase was due primarily to increased contract manufacturing revenue and higher direct product sales to the regenerative medicine and biobanking markets. In addition, the increase in the total revenue for the first half of 2013 included license revenue of $0.6 million.

    Gross margin as a percentage of revenue decreased to 35.6% and 43.5%, respectively, in the second quarter and first half of 2013 compared to 41.5% and 48.9% for the same periods in 2012. The decrease was due primarily to the increase in contract manufacturing product sales, which has a higher cost of sales, compared to core product sales, offset by recognition of the license revenue during the first quarter with no associated costs.

    Operating expenses in the second quarter and first half of 2013 were $0.9 million and $1.8 million, respectively, compared with $0.8 million and $1.4 million for the same periods of 2012. This increase was primarily attributable to higher corporate costs, higher depreciation and rent costs related to the new facility, and higher office-related expenses.

    During the second quarter of 2013 and the first half of 2013, the Company reported an operating loss of $0.08 million and operating income of $0.1 million, compared to operating losses of $0.3 million and $0.5 million in the second quarter and first half of 2012. Net loss was $0.3 million, or $0.00 per share, for each of the second quarter and first half of 2013, compared to a loss of $0.5 million, or $0.01 per share, for the second quarter of 2012 and $0.8 million, or $0.01 per share, in the first half of 2012, respectively.

    Outlook for 2013We continue to expect total 2013 revenue to be in the range of $6.5 million to $7.0 million, with gross margin as a percentage of revenue of approximately 38% - $41%, and increased operating expenses in 2013 of 10% - 20% over 2012. We continue to expect improvement in operating and net income (loss) over 2012. We believe cash generated from customer collections will provide sufficient funds to operate our business.

    BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit, and follow BioLife on Twitter.

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our financial and business outlook for 2013, and other anticipated developments related to us, our business or customers. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. Media & Investor RelationsDaphne TaylorSenior Vice President, Chief Financial Officer(425) 402-1400  


    BioLife Solutions, Inc.Statement of OperationsThree MonthsEnded June 30,Six MonthsEnded June 30,20132012 


    2012RevenueProduct sales





    1,923,289Licensing revenue––5,000609,16710,000Total revenue2,330,0181,097,4094,490,0301,933,289Cost of product sales1,501,575641,7482,536,103987,877Gross profit823,443455,6611,953,927945,412Operating expensesResearch and development94,908126,627200,876243,148Sales and marketing214,762160,658417,250234,039General and administrative601,917475,0061,226,044954,119Total operating expenses911,287762,2911,844,4401,431,306Operating income (loss)(82,844)(306,630)109,487(485,894)Other income (expenses)Other income ––5,981––94,253Interest expense(185,555)(183,543)(371,110)(362,320)Loss on disposal of property and equipment––––––(63)Amortization of deferred financing costs(14,107)(14,701)(28,059)(41,743)Total other income (expenses)(199,662)(192,263)(399,169)(309,876)Net Loss






    (795,770)Basic and diluted net loss per common share






    (0.01)Basic and diluted weighted average common shares used to calculate net loss per common share70,035,71069,679,85469,954,65469,679,854 

      Selected Balance Sheet DataJune 30,December 31,20132012Cash and cash equivalents$


    196,478Accounts receivable980,974600,153Inventories593,138656,397Total current assets1,815,6091,627,759Total current liabilities1,423,1921,365,338Promissory notes payable, related parties10,603,12710,603,127Accrued interest, related parties3,130,5012,759,391Total liabilities16,099,77515,655,852Total shareholders' equity (deficiency)(12,662,694)(12,486,023) 

      Selected Cash Flow DataSix Months Ended June 30, 20132012Cash provided by operating activities$


    686,007Cash used in investing activities(225,723)(1,022,517)Cash provided by financing activities25,458475,000Net increase (decrease) in cash and equivalents(120,273)138,490 

    SOURCE BioLife Solutions, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. BioLife Solutions Announces Strategic Partnership with HemaCare
    2. BioLife Solutions Named One of Washingtons Best Companies
    3. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
    4. BioLife Solutions Announces License Agreement
    5. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
    6. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
    7. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
    8. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
    9. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
    10. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
    11. BioLife Solutions 2011 Revenue Up 33%
    Post Your Comments:
    (Date:3/28/2017)... 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), ... novel therapies for metabolic and endocrine disorders, today announced ... Ph.D., will deliver a corporate presentation at H.C. Wainwright ... being held April 3, 2017 at the St. Regis ... this presentation are as follows: ...
    (Date:3/28/2017)... 28, 2017 Focus is ... sector due to the scientifically intensive operations of ... agricultural, environmental, and industrial. In today,s pre-market research, ... Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera ... (NASDAQ: OCUL ). Learn more about ...
    (Date:3/27/2017)... -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company ... foodborne pathogens,  today announced that Mary Duseau , CEO ... on March 29 at 9:50am ET. The conference will be ... About Roka Bioscience ... Roka Bioscience is a molecular diagnostics company ...
    (Date:3/27/2017)... Md. , March 27, 2017  The ... billion for 2016, according to a new report ... medical lab testing is performed to evaluate disease ... individual therapy, among other reasons.  The healthcare market ... Market , provides an overview of the ...
    Breaking Biology Technology:
    (Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
    (Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
    (Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
    Breaking Biology News(10 mins):